Zogenix, Inc. (NASDAQ:ZGNX) Shares Sold by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC reduced its stake in shares of Zogenix, Inc. (NASDAQ:ZGNX) by 48.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 812 shares of the company’s stock after selling 771 shares during the period. Tower Research Capital LLC TRC’s holdings in Zogenix were worth $33,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Zogenix in the 1st quarter valued at about $193,000. SG Americas Securities LLC increased its holdings in Zogenix by 113.6% in the second quarter. SG Americas Securities LLC now owns 14,226 shares of the company’s stock valued at $680,000 after buying an additional 7,566 shares during the last quarter. First Trust Advisors LP acquired a new stake in Zogenix during the second quarter valued at approximately $1,870,000. Aperio Group LLC raised its stake in Zogenix by 14.9% during the second quarter. Aperio Group LLC now owns 5,875 shares of the company’s stock valued at $281,000 after buying an additional 762 shares in the last quarter. Finally, Advisor Group Inc. lifted its holdings in Zogenix by 383.1% during the 2nd quarter. Advisor Group Inc. now owns 942 shares of the company’s stock worth $45,000 after buying an additional 747 shares during the last quarter.

In other Zogenix news, CEO Stephen J. Farr sold 34,225 shares of Zogenix stock in a transaction on Monday, November 25th. The stock was sold at an average price of $50.00, for a total transaction of $1,711,250.00. Following the sale, the chief executive officer now owns 90,752 shares of the company’s stock, valued at approximately $4,537,600. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Michael P. Smith sold 15,000 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $48.00, for a total value of $720,000.00. Following the transaction, the chief financial officer now owns 16,387 shares of the company’s stock, valued at approximately $786,576. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,225 shares of company stock valued at $2,681,250. 4.40% of the stock is owned by insiders.

Several research analysts have recently commented on ZGNX shares. ValuEngine lowered Zogenix from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 28th. Needham & Company LLC assumed coverage on Zogenix in a research report on Monday, October 21st. They set a “buy” rating and a $58.00 price target on the stock. BidaskClub upgraded Zogenix from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 27th. Piper Jaffray Companies set a $64.00 price objective on shares of Zogenix and gave the stock a “buy” rating in a report on Monday, August 26th. Finally, Northland Securities reiterated a “buy” rating on shares of Zogenix in a research note on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $59.70.

ZGNX stock opened at $45.58 on Friday. Zogenix, Inc. has a 1 year low of $33.43 and a 1 year high of $56.50. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -14.11 and a beta of 1.97. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.00 and a current ratio of 3.00. The stock’s fifty day moving average is $45.25 and its two-hundred day moving average is $44.10.

Zogenix (NASDAQ:ZGNX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($6.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($5.70). The company had revenue of $0.63 million for the quarter, compared to analyst estimates of $0.39 million. During the same quarter in the previous year, the business posted ($1.08) earnings per share. As a group, analysts predict that Zogenix, Inc. will post -3.73 EPS for the current fiscal year.

Zogenix Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

See Also: How to Invest in Marijuana Stocks

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.